Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Description: Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Summary

The publisher has released its new PharmaPoint Drug Evaluation report, "Benralizumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

AstraZeneca's benralizumab is a humanized immunoglobulin G1 (IgG1) mAb targeting the interleukin-5 receptor alpha subunit (IL-5Ra), which results in antibody-dependent cell-mediated cytotoxicity that induces apoptosis, leading to eosinophil and basophil depletion. It has been shown that reducing eosinophilic inflammation decreases the frequency and severity of asthma exacerbations (Haldar et al., 2009). There is relatively long-lasting depletion of peripheral blood eosinophils after either IV or SC administration of benralizumab; in particular, this effect persisted for at least two to three months in individuals receiving doses ranging from 0.03-3mg/kg (Busse et al., 2010).

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Benralizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Benralizumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Benralizumab performance
- Obtain sales forecast for Benralizumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
  2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
  3.1 Etiology and Pathophysiology
    3.1.1 Etiology
    3.1.2 Pathophysiology
    3.1.3 Prognosis
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
Table 6: Leading Treatments for Asthma, 2014
Table 7: Unmet Need and Opportunity in Asthma
Table 8: Asthma - Late Stage Pipeline, 2014
Table 9: Product Profile - Benralizumab
Table 10: Efficacy of Benralizumab Versus Placebo
Table 11: Benralizumab SWOT Analysis, 2014
Table 12: Global Sales Forecast ($) for Benralizumab, 2013-2023
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Stepwise Disease Management Approach for Asthma in Adults
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023

Ordering: 
Order Online - [http://www.researchandmarkets.com/reports/2989092/](http://www.researchandmarkets.com/reports/2989092/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Benralizumab (Asthma) - Forecast and Market Analysis to 2023
Web Address: http://www.researchandmarkets.com/reports/2989092/
Office Code: SCD2STNL

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: __________________________________________ Last Name: __________________________________________
Email Address: * _______________________________________
Job Title: _____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _________________________________________________
Postal / Zip Code: _____________________________________
Country: ______________________________________________
Phone Number: _________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp